Sign in
MLYS Stock Price, Chart, Stats & News
Mineralys Therapeutics, Inc.
Save
1.77B
Market cap
–
Current P/E
–
Forward P/E
MLYS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -23.37% |
ROE | -32.94% |
D/E | – |
Interest coverage ratio | – |
MLYS valuation
P/E | – |
P/S | – |
P/B | 2.95x |
P/CF | -13.39x |
P/FCF | -11.02x |
P/OCF | -13.39x |
PEG | -0.63x |
EV multiple | -10.48x |
About
Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials. Its primary focus lies in creating innovative treatments for high blood pressure and its related cardiovascular complications. The company's leading investigational drug is lorundrostat.
Similar securities
Based on sector and market capitalization
Report issue